Best Peptides for Men: Muscle, Fat Loss, Recovery, Libido and Sleep, With a Dosage Chart

Peptides do not sort by sex. They sort by goal, and the honest version of "best peptides for men" is a list of the six goals men actually arrive with and the compounds that map to each. What makes the male version of this question different is the goal mix, not the biology: more requests for lean mass and libido, fewer for skin, and a persistent assumption that a peptide will do something to testosterone. Most of them will not, which gets its own section below.

This page sets out the goal to compound map with a dosage chart, what stacks together, what the evidence actually supports for each, and where to buy. It is research use information, not a protocol to follow. The peptides for women page runs the same exercise with a different goal mix.

What men actually come looking for

Across the Bureau's search and email data, six goals cover almost everything: lean mass and strength, fat loss, injury recovery, libido, sleep, and hair. They are not equally well served. Fat loss has the only peptides in the category with phase 3 trials behind them. Recovery has the loudest community and almost no human evidence. Sleep and hair sit in between. That spread matters more than any ranking, because the gap between the best-evidenced and worst-evidenced item on the list is the gap between a licensed drug and a forum consensus.

The goal to compound map

Protocols below are the ones reported in practice and, where an approved human dose exists, the approved one. They are descriptions, not recommendations.

Muscle and strength

Everything in this column works the same way: it tells the pituitary to release its own growth hormone rather than supplying GH from outside. CJC-1295 without DAC is a GHRH analogue with a short half-life, ipamorelin is a selective ghrelin receptor agonist, and pairing them hits two receptors on the same cell at once, which is why the combination is the default rather than either alone. The reported protocol is 100 mcg of each before sleep, fasted, because that is when the body's own largest GH pulse occurs and because carbohydrate blunts it. The CJC-1295 and ipamorelin stack page and the ipamorelin dosage page have the arithmetic.

What that delivers is worth stating plainly. Raising GH and IGF-1 is well established for this class. Translating it into strength is not. The cleanest long-run human evidence comes from a two year trial of MK-677, a non-peptide ghrelin agonist, in adults around 65: lean body mass rose, but a strength or function benefit was not demonstrated. Early weight gain on any secretagogue is substantially water and glycogen, which is why nobody should judge a protocol at week three.

The ceiling is lower than the marketing implies. These compounds nudge a natural pulse; they do not replicate exogenous GH and are nowhere near anabolic steroids on effect size, which peptides vs steroids sets out. For the full list including GHRP-6 and IGF-1 LR3 see muscle growth peptides and the best peptide stack for muscle growth.

Fat loss, and the weight loss peptides men ask for

This is the one goal where the evidence is genuinely strong, and it belongs to a single class: the incretin receptor agonists. Semaglutide at 2.4 mg weekly produced roughly 15 percent body weight reduction over 68 weeks in the STEP programme. Tirzepatide, a dual GIP and GLP-1 agonist, reached roughly 20 to 22 percent at 15 mg weekly. Retatrutide, which adds glucagon agonism, reported around 24 percent at 12 mg in phase 2. Those are trial figures with placebo arms, which is not a sentence that can be written about most of this category. The weight loss peptides page compares them and the tirzepatide dosage guide covers escalation.

Two things men get wrong here. A 20 percent weight loss is not a 20 percent fat loss: a steep deficit takes lean tissue with it unless resistance training and protein intake are deliberately held up, and no peptide prevents that. And the escalation schedule exists to let the gut adapt, so skipping steps buys nausea rather than speed.

Tesamorelin is the specialist. At 2 mg daily it is the only growth hormone peptide with an approved indication, for visceral adipose tissue in HIV-associated lipodystrophy, where it reduced visceral fat over 26 weeks against placebo. For a man whose complaint is abdominal visceral fat rather than total body weight, it is the one with an actual trial behind it. AOD-9604 and HGH fragment 176-191 are the cheap lipolysis options at 250 to 500 mcg daily fasted, and the phase 2 oral data on AOD-9604 was inconsistent. A tier below. More at best peptides for fat loss.

Recovery, joints and tendons

BPC-157 and TB-500 are the two compounds this category runs on, and together they are the most popular and least evidenced pairing in the research peptide market. BPC-157 is a 15 residue fragment of a gastric protein with a large rodent literature and no published human trials; the reported protocol is 250 to 500 mcg daily, often split, which is well above the roughly 110 mcg a body surface area conversion of the rodent dose gives for a 70 kg adult, a gap the BPC-157 dosage page works through honestly. TB-500 runs at 2 to 5 mg twice weekly for a four to six week loading block then weekly, near 0.1 mg per kilogram per week; see the TB-500 dosage page.

Together they are sold as the Wolverine stack, on the argument that they act on different parts of repair: BPC-157 locally on angiogenesis, TB-500 systemically on actin and cell migration. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend both for the 503A bulks list, against its own reviewers who cited limited effectiveness evidence. That is the state of the evidence: a narrow committee vote over staff objection, not a trial. More at recovery peptides.

Libido and erectile function

PT-141, bremelanotide, is the only peptide in this category with a regulatory approval anywhere. It is a melanocortin receptor agonist and it works centrally, in the brain, rather than on blood flow, which makes it mechanistically different from every PDE5 inhibitor and the reason it gets attention for low desire rather than a plumbing problem. It is approved as Vyleesi for acquired generalised hypoactive sexual desire disorder in premenopausal women, at 1.75 mg subcutaneously, no more than one dose in 24 hours and no more than eight a month.

For men the position is weaker. The original intranasal development for erectile dysfunction was halted over blood pressure increases, and the subcutaneous male data sits at phase 2. The protocol reported in practice is 1 to 2 mg subcutaneously 30 to 60 minutes before, used occasionally rather than daily, with nausea and flushing common and a transient blood pressure rise as the one that matters. Anyone with uncontrolled hypertension is exactly who the halted trial was about. The PT-141 guide and peptides for erectile dysfunction go through it. Persistent ED is a vascular and endocrine warning sign before it is a peptide question, and it deserves a clinician rather than a vial.

Sleep and hair

DSIP, delta sleep-inducing peptide, is the sleep compound, reported at 100 to 200 mcg subcutaneously 30 to 60 minutes before bed. The human data is thin to the point of being decorative, and the reports describe deeper sleep and faster onset rather than more total hours. Epithalon is the other name that appears, at 5 to 10 mg daily for 10 to 20 day blocks a couple of times a year. A useful cross-check: the GH secretagogues above are dosed before sleep anyway, and several men report that as the sleep improvement, which can make a separate sleep compound redundant. See top peptides for sleep and the DSIP guide.

Hair needs the firmest hand. GHK-Cu is the peptide in play, subcutaneously at 1 to 2 mg or topically, and its two controlled human trials are topical and for skin, not hair. Male pattern hair loss is driven by DHT at the follicle, and nothing in the peptide category addresses that mechanism. A copper peptide may support the scalp environment; it will not reverse a receding hairline. Judge nothing before three to six months, the follicle cycle's pace. The hair loss page covers the mesotherapy figures.

What to stack, and what not to

The rule for combining is simple: compounds on separate axes stack cleanly, compounds on the same axis compete or add side effects without adding effect.

Two structural points. Run one new compound at a time for the first two weeks of any block, or an adverse effect cannot be attributed to anything. And keep cycles finite: four to twelve weeks on with a comparable break is the pattern across the category, covered in the cycle length guide, less because of proven receptor desensitisation than because an unstudied compound earns the conservative schedule.

Testosterone: what peptides do and do not do

This is the assumption that needs dismantling, because it is sold hard and it is mostly wrong.

The growth hormone peptides do nothing to testosterone. Sermorelin, CJC-1295, ipamorelin, tesamorelin, GHRP-6 and the non-peptide MK-677 all act on the growth hormone axis, through the GHRH receptor or the ghrelin receptor GHSR-1a, and raise GH and IGF-1. Testosterone comes off a different axis entirely, the hypothalamic-pituitary-gonadal one, and nothing in that list touches it. A vendor page implying otherwise is describing a hope.

Kisspeptin is the exception, with caveats. Kisspeptin neurons sit upstream of GnRH and are the switch that starts the HPG cascade. Published human work, largely out of Imperial College London, showed kisspeptin infusions raise LH and testosterone in healthy men. Those were intravenous research protocols with no established subcutaneous dose to carry over, so kisspeptin-10 on a research shelf is a real mechanism without a real protocol.

Two things men expect to find here are not peptides. hCG works as an LH analogue and does raise intratesticular testosterone, but it is a glycoprotein of 237 residues and a prescription drug. Enclomiphene raises LH and FSH by blocking estrogen feedback, but it is a small molecule SERM. Both are covered in is it a peptide.

The one real indirect route is fat loss. Obesity lowers total and free testosterone in men, and a meaningful reduction in body fat reverses part of it. So an incretin agonist can end up raising testosterone by way of the fat it removes, not by anything it does to the gonadal axis. That is a slow second-order effect. None of it substitutes for testosterone replacement therapy, which is a prescription treatment and a conversation with a clinician, not a vial from a research vendor.

Realistic expectations

Where to buy

Disclosure. Links in this section may earn the Bureau a commission. The scorecard weighs documentation, consistency, shipping and price, and the method is on the vendor scorecard page. Prices are list prices checked 2026-09-08 and change without notice.

• Amino Club, CJC-1295 and ipamorelin blend, 10mg, $59.99: the readers' pick for the muscle column, batch COA on every product page, code 100 for 20% off a first order. Amino Club review.
• Amino Club, tirzepatide (listed as GLP-2), 30mg, $59.99: $2.00 per mg, the lowest the Bureau tracks on the compound.
• Amino Club, BPC-157, 10mg, $39.99 and PSPeptides, TB-500: the repair pair. PSPeptides is the only scorecard vendor shipping outside the US, and code PEPTIDEBUREAU takes 10% off.
• Amino Club, PT-141, 10mg, $29.99: $3.00 per mg, lowest of the four vendors tracked for it. PT-141 guide.
• Amino Club, DSIP, 5mg, $29.99 and Amino Club, GHK-Cu, 50mg, $29.99: the sleep and scalp end, GHK-Cu at $0.60 per mg.
• Pantheon Peptides, tesamorelin: third-party lab verified, COA linked on the product page. Pantheon review.

Whatever you buy, check that the vendor publishes a batch-specific certificate of analysis rather than a generic one, and read how to buy peptides and how to spot a fake vendor before a first order. These are research compounds and nothing here is medical advice.

Key Takeaways

• Peptides sort by goal, not by sex, and only the incretin agonists and tesamorelin have approved human indications. Everything else here is research grade
• CJC-1295 with ipamorelin at 100 mcg each before sleep is the default lean mass pairing, and the ceiling is a nudged GH pulse, not a steroid
• Tirzepatide and retatrutide lead fat loss at 20 to 24 percent in trials; tesamorelin at 2 mg daily is the visceral fat specialist
• BPC-157 at 250 to 500 mcg daily and TB-500 at 2 to 5 mg twice weekly are the most popular and least evidenced pairing in the category
• Growth hormone peptides do not raise testosterone. Kisspeptin has the mechanism but no established subcutaneous protocol, and hCG and enclomiphene are not peptides
• Stack across axes, never two secretagogues on the same receptor, and add one new compound at a time

Frequently Asked Questions

What are the best peptides for men?

There is no single answer, because the compounds sort by goal rather than by sex. For lean mass and recovery the growth hormone secretagogues dominate, usually a CJC-1295 and ipamorelin pairing at 100 mcg of each before sleep. For fat loss the incretin agonists have by far the strongest evidence, with tirzepatide and retatrutide leading. For tissue repair it is BPC-157 at 250 to 500 mcg daily, often with TB-500. For libido it is PT-141. For sleep it is DSIP at 100 to 200 mcg before bed. Only the incretin class and tesamorelin have approved human indications behind them; everything else on that list is research grade with animal data or forum reports.

What are the best weight loss peptides for men?

The incretin receptor agonists, and it is not close. Semaglutide produced about 15 percent body weight reduction over 68 weeks in the STEP programme at 2.4 mg weekly, tirzepatide reached roughly 20 to 22 percent at 15 mg weekly, and retatrutide reported around 24 percent at 12 mg in phase 2. Tesamorelin is the specialist option for visceral fat specifically, at 2 mg daily, and is the only growth hormone peptide with an approved indication. AOD-9604 and HGH fragment 176-191 are marketed for fat loss on a beta-3 lipolysis mechanism, but the phase 2 human data for AOD-9604 was inconsistent, and neither belongs in the same tier.

Do peptides raise testosterone?

Almost none of them do, and the ones men are usually sold do not. Sermorelin, CJC-1295, ipamorelin, tesamorelin and GHRP-6 act on the growth hormone axis, through the GHRH receptor or the ghrelin receptor, and raise GH and IGF-1. That is a different axis from the one that produces testosterone, and they do not raise it. Kisspeptin is the one peptide with a genuine published mechanism, sitting upstream of GnRH, and infusion studies in healthy men raised LH and testosterone, though those were intravenous research protocols rather than an established subcutaneous one. hCG works as an LH analogue and does raise intratesticular testosterone, but it is a glycoprotein and a prescription drug rather than a research peptide. The one real indirect route is fat loss: obesity lowers total and free testosterone in men, and losing a meaningful amount of body fat reverses part of that.

What is the best peptide stack for muscle growth and fat loss at the same time?

The pairing reported most often is a growth hormone secretagogue for the lean mass side and an incretin agonist or tesamorelin for the fat side, run together because they work on separate axes and do not compete. In practice that means CJC-1295 with ipamorelin at 100 mcg each before sleep, alongside either tirzepatide weekly or tesamorelin at 2 mg daily. The trade-off is real: an aggressive calorie deficit from a GLP-1 drug costs lean mass unless resistance training and protein intake are held up, and no peptide in the stack prevents that. Nobody has tested this combination in a trial, so it is a description of practice, not a validated protocol.

How long do peptides take to work for men?

It depends entirely on which end of the evidence base you are on. PT-141 acts within about 45 minutes of a single dose. Incretin agonists start suppressing appetite within the first few weeks but the trial weight loss curves run 48 to 68 weeks and do not plateau early. Growth hormone secretagogues raise IGF-1 within days, but body composition change is judged at 8 to 12 weeks and the two year MK-677 trial in older adults found lean mass gains without a demonstrated strength benefit. BPC-157 and TB-500 blocks are reported at 2 to 8 weeks, with no human trial to anchor that. Hair is the slowest of all, judged at three to six months because that is the pace of the follicle cycle.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.